Cargando…
Effects of CRN04894, a Nonpeptide Orally Bioavailable ACTH Antagonist, on Corticosterone in Rodent Models of ACTH Excess
CRN04894 is an orally administered nonpeptide that is a potent and selective antagonist for adrenocorticotropic hormone (ACTH) acting at the melanocortin 2 receptor (MC2R) and is currently under development for the treatment of diseases of ACTH excess such as Cushing’s disease, congenital adrenal hy...
Autores principales: | Fowler, Melissa A, Kusnetzow, Ana Karin, Han, Sangdon, Reinhart, Greg, Kim, Sun Hee, Johns, Michael, Kredel, Taylor A, Antwan, Agnes, Athanacio, Jon, Tsivkovski, Oleg, Luo, Rosa, Madan, Ajay, Zhu, Yun Fei, Betz, Stephen F, Struthers, Scott, Markison, Stacy |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8090401/ http://dx.doi.org/10.1210/jendso/bvab048.337 |
Ejemplares similares
-
SAT-364 Nonpeptide Orally-Bioavailable ACTH Antagonists: Suppression of ACTH-Induced Corticosterone Secretion and Adrenal Hypertrophy in Rats
por: Kusnetzow, Ana, et al.
Publicado: (2019) -
OR19-03 Effects of Nonpeptide Orally Bioavailable ACTH Antagonists on Adrenal Gland Size and Function in Rats
por: Markison, Stacy, et al.
Publicado: (2020) -
OR12-2 Inhibition of Basal and ACTH-stimulated Cortisol Secretion in Humans Using an Oral Nonpeptide ACTH Antagonist (CRN04894)
por: Betz, Stephen, et al.
Publicado: (2022) -
MON-176 Discovery and Identification of Late Stage Selective Nonpeptide ACTH Antagonists for the Treatment of Cushing’s Disease, Ectopic ACTH Secreting Tumors, and Congenital Adrenal Hyperplasia
por: Kusnetzow, Ana Karin, et al.
Publicado: (2020) -
MON-089 Discovery and Identification of Late Stage Selective Nonpeptide Somatostatin Subtype 5 (sst5) Agonists for the Treatment of Hyperinsulinemic Hypoglycemia
por: Fowler, Melissa A, et al.
Publicado: (2020)